



FOR IMMEDIATE RELEASE

Teleconference/Webcast: Investor Briefing – Licensing and development agreement with European partner, Hospira

MELBOURNE, Australia, and MENLO PARK, California U.S.A. (December 14, 2009) – ChemGenex Pharmaceuticals Limited (ChemGenex) (ASX:CXS) will host an investor briefing teleconference tomorrow, Tuesday 15th December at 11:00am Australian Eastern Daylight Savings Time (Monday 10th December 4:00pm U.S. Pacific Time).

ChemGenex CEO Dr. Greg Collier will update investors on the development and commercialization agreement that ChemGenex has signed with Hospira Inc. for the commercialization of omacetaxine in Europe, the Middle East and parts of Africa.

If you would like to attend the call we request that you register your interest with Kyahn Williamson of Buchan Consulting – kwilliamson@bcq.com.au or telephone 03 9866 4722.

Teleconference details:

Domestic access (toll free) details are below:

Access Number:	02 8212 8410
Toll Free Number:	1800 153 721
Participant Pin Code:	189117#

International access (toll free) details are below:

0800 442 709	New Zealand
800 616 2259	Singapore
800 933 733	Hong Kong
001 803 011 3830	Indonesia
0034 800 400746	Japan
1866 307 0659	USA/Canada
0808 2389 067	UK
0800 000 3882	Germany
0805 100 294	France
0800 000 601	Switzerland

If you would like to dial-in from other locations please contact Kyahn Williamson.

About ChemGenex Pharmaceuticals Limited (<http://www.chemgenex.com>)

ChemGenex is an oncology focused biopharmaceutical company developing small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The company

For personal use only

is developing omacetaxine, its lead product candidate, for the treatment of patients with Chronic Myeloid Leukemia (CML), Acute Myeloid Leukemia (AML), and Myelodysplastic Syndrome (MDS). A New Drug Application has been accepted by the U.S. Food and Drug Administration and a Marketing Authorisation Application has been validated by the European Medicines Agency for CML patients with the Bcr-Abl T315I mutation. ChemGenex has established a corporate alliance with Hospira to develop and commercialize omacetaxine in Europe, the Middle East and parts of Africa, and is seeking to establish commercial partnerships in the rest of the world. ChemGenex plans to commercialize omacetaxine itself in North America. ChemGenex currently trades on the Australian Stock Exchange under the symbol "CXS". For additional information on ChemGenex Pharmaceuticals, please visit the company's website at <http://www.chemgenex.com>.

Contacts

ChemGenex Information
Dr. Greg Collier
CEO and Managing Director
Cell (Australia): +61 419 897501
Cell (USA): +1 650 200 8145
Email:
gcollier@chemgenex.com

Investor Relations – Australia
Kyahn Williamson
Buchan Consulting
Tel: +61 (0)3 9866 4722
Cell: + 61 (0)401 018 828
Email:
kwilliamson@bcg.com.au

Investor Relations – USA
Remy Bernarda
Blueprint Life Science Group
Tel: +1.415.375.3340 x 2022
Cell: +1.415.203.6386
Email:
rbernarda@bplifescience.com

Safe Harbor Statement

Certain statements made herein (including for this purpose sites to which a hyperlink has been provided) that use the words "estimate", "project", "intend", "expect", "believe" and similar expressions are intended to identify forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties which could cause the actual results, performance or achievements of the company to be materially different from those which may be expressed or implied by such statements, including, among others, risks or uncertainties associated with the development of the company's technology, the ability to successfully market products in the clinical pipeline, the ability to advance promising therapeutics through clinical trials, the ability to establish our fully integrated technologies, the ability to enter into additional collaborations and strategic alliances and expand current collaborations and obtain milestone payments, the suitability of internally discovered genes for drug development, the ability of the company to meet its financial requirements, the ability of the company to protect its proprietary technology, potential limitations on the company's technology, the market for the company's products, government regulation in Australia and the United States, changes in tax and other laws, changes in competition and the loss of key personnel. These statements are based on our management's current expectations and are subject to a number of uncertainties that could change the results described in the forward-looking statements. Investors should be aware that there are no assurances that results will not differ from those projected.

###